Thus, in multiple different lung adenocarcinoma models with different driver oncogenes and p53 co-mutations development of CDDP resistance generated a remarkable vulnerability to perturbation of glucose metabolism. This evidence concerns the gene TP53 and lung adenocarcinoma.